Concepedia

Flat Dosing

Flat Dosing is a dosing strategy in oncology therapeutics wherein a fixed dose of an immuno-oncology agent is administered to all patients regardless of individual body size or surface area, contrasting with weight- or surface area-based dosing regimens.

22

Publications

1.4K

Citations

202

Authors

101

Institutions

Publications per year

2017–2026

11

Variants

Fixed Dosing

Parents

Publications

22

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Xiaochen Zhao, Satyendra Suryawanshi, Matthew Hruska et al. · Annals of Oncology · 2017 · 235 citations · Full text

, , +17

Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

Amar Gajjar, Clinton F. Stewart, David W. Ellison et al. · Clinical Cancer Research · 2013 · 215 citations · Full text

, , +17

A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

Christine Hartford, Apurva A. Desai, Linda Janisch et al. · Clinical Cancer Research · 2009 · 88 citations · Full text

, , +14

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Bart C. Kuenen, Petronella O. Witteveen, Rita Ruijter et al. · Clinical Cancer Research · 2010 · 86 citations · Full text

, , +17

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Daan P. Hurkmans, Edwin A. Basak, Tanja C. van Dijk et al. · Journal for ImmunoTherapy of Cancer · 2019 · 82 citations · Full text

, , +14

1–5 of 22

Authors

202

  1. MH
    Matthew Hruska

    Bristol-Myers Squibb (United States), United States

    2 publications · 255 citations

    2

    h-index

  2. JV
    Jaap Verweij

    Rotterdam University of Applied Sciences, Netherlands

    2 publications · 122 citations

    2

    h-index

  3. RH
    Ron H.J. Mathijssen

    Erasmus MC Cancer Institute, Netherlands

    2 publications · 133 citations

    2

    h-index

  4. AR
    Amit Roy

    Bristol-Myers Squibb (United States), United States

    2 publications · 255 citations

    2

    h-index

  5. MJ
    Mark J. Ratain

    University of Chicago, United States

    2 publications · 166 citations

    2

    h-index

1–5 of 202

Institutions

101

  1. Erasmus MC Cancer Institute

    Rotterdam, The Netherlands

    3 h-index

    21 publications

    1.5K citations

  2. Erasmus MC

    Rotterdam, The Netherlands

    3 h-index

    16 publications

    1.2K citations

  3. National Cancer Institute

    Bethesda, United States

    2 h-index

    12 publications

    2.4K citations

  4. The Netherlands Cancer Institute

    Amsterdam, The Netherlands

    2 h-index

    8 publications

    396 citations

  5. Bristol-Myers Squibb (United States)

    New York, United States

    2 h-index

    4 publications

    295 citations

  6. Clinical Research Institute

    Plymouth, United States

    1 h-index

    1 publications

    34 citations

  7. Indiana University – Purdue University Indianapolis

    Indianapolis, United States

    1 h-index

    1 publications

    76 citations

  8. Lurie Children's Hospital

    Chicago, United States

    1 h-index

    13 publications

    2.8K citations

1–8 of 101

Venues

  1. Clinical Cancer Research

    7 publications · 591 citations

    7

    h-index

  2. Journal of Clinical Oncology

    4 publications · 189 citations

    4

    h-index

  3. Clinical Infectious Diseases

    CID · 1 publications · 16 citations

    1

    h-index

  4. Annals of Oncology

    1 publications · 235 citations

    1

    h-index

  5. Blood

    1 publications · 13 citations

    1

    h-index

1–5